Dynamic Biomarker Panels for On-Treatment Immunotherapy Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for predicting patient response to PD-1 pathway inhibitors in cancer treatment are inadequate, with existing biomarkers failing to accurately identify responders and non-responders, leading to unnecessary therapy and increased toxicity, and invasive biopsies being risky and impractical for routine use.
Innovation Solution
A panel of biomarkers, including proteins such as IL-6, CRP, and CXCL10, measured using ultrasensitive techniques, is used to compare pre-treatment and on-treatment levels to generate an IO response score, guiding therapy selection and personalizing treatment plans based on dynamic changes in the immune response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If pre-treatment biomarkers (such as PD-L1 IHC) are used to predict response to PD-1 inhibitors, then patient selection is improved, but more than half of patients with high tumor PD-L1 still will not benefit
Solution Approach 1:
The patent segments the single PD-L1 biomarker assessment into multiple distinct biomarker measurements taken at different time points (pre-treatment baseline, on-treatment at cycle 1 and cycle 2). This includes measuring multiple proteins (PD-L1, PD-1, TIM-3, LAG-3, IDO1, INHBA) to create a comprehensive biomarker panel that tracks dynamic changes in the immune response, thereby improving both prediction accuracy and treatment benefit reliability
Solution Approach 2:
The patent performs preliminary baseline measurements of multiple biomarkers before treatment begins, establishing individual patient set-points. This preliminary action enables comparison of on-treatment changes against personalized baselines, allowing early identification of responders and non-responders before significant toxicity accumulates or treatment cycles are wasted
2Reliability
If combination therapy with multiple I-O agents is used to increase response rates, then response rates are improved, but rates of toxicities including immune adverse effects increase
Solution Approach 1:
The patent implements a feedback mechanism by measuring biomarker levels on-treatment (at cycles 1 and 2) and comparing them to baseline. The direction and magnitude of change in biomarkers (increases or decreases) provide real-time feedback on treatment response, enabling dynamic adjustment of therapy to maintain efficacy while minimizing unnecessary toxicity exposure in non-responders
Solution Approach 2:
The patent transitions from static pre-treatment biomarker assessment to dynamic on-treatment monitoring. By tracking changes in multiple biomarkers over time (baseline, cycle 1, cycle 2), the system adapts treatment decisions based on the patient's evolving immune response, allowing optimization of the efficacy-toxicity ratio throughout the treatment course
3Measurement precision
If invasive biopsies are performed for biomarker assessment, then tissue-based prediction accuracy is improved, but the procedure becomes risky and impractical for routine use
Solution Approach 1:
The patent uses peripheral blood as an intermediary medium to indirectly assess the immune response to treatment. Instead of directly sampling tumor tissue through invasive biopsy, the system measures biomarkers in circulating blood, which reflects the systemic immune response to the immunotherapy, thereby maintaining high prediction accuracy while dramatically improving ease of operation and routine usability
Data Source
AI summary
Biomarker panels for the prediction of patient response to immunotherapy, and methods of use thereof.